PBAC's latest decision on Escitalopram: Recommended (2014). Considered for Major depressive disorders, generalised anxiety disorder, and social anxiety disorder. The submission requested listing of a new 20 mg/mL oral liquid strength as a Restricted benefit.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2007
Submissions
2
2007 → 2014
Eligible population
Patients with major depressive disorders, moderate to severe generalised anxiety disorder (GAD), or moderate to severe social anxiety disorder (SAD) as defined by DSM-V criteria who have not responded to non-pharmacological therapy and either have a GP Mental Health Care Plan or have been assessed by a psychiatrist.
Therapy area
Mental health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
No economic analysis was presented in this submission; this is a minor submission for a new strength formulation with no comparative effectiveness or economic evaluation.